A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774

This study is testing a combination of two drugs, temozolomide and a new experimental medication called M1774, to see if they can better control advanced cancer. By working together, these drugs aim to stop cancer cells from repairing themselves and help shrink or stabilize tumors more effectively than using one drug alone.

This trial is for adults with advanced, spreading solid tumors or specific types of colorectal cancer that have continued to grow after previous treatments. You must meet specific health and genetic testing requirements, and you cannot have been treated with these specific study drugs before.

Participants will receive the study medications and undergo regular health checks, which include blood tests, tissue biopsies, and imaging scans like CT or MRI to monitor how the tumor responds. The study team will closely observe you to determine the right dose and track any side effects to ensure your safety.

This trial is currently recruiting patients at medical centers in Irvine, La Jolla, and Orange, California. It is a combined Phase 1 and 2 study, meaning researchers are looking at both safety and how well the treatment works.